Fios Genomics published an Oncology Data Analysis Demo Report demonstrating how bioinformatics applied to a clinical oncology study revealed pivotal insights from complex biomarker data.
Public source
Publisher name
Public post
In our Oncology Data Analysis Demo Report, we demonstrate how applying bioinformatics to a clinical oncology study revealed pivotal insights from complex biomarker data.…
Company
Fios Genomics
Analyse - Interpret - Integrate
- Industry
- Biotechnology Research
- Location
- Edinburgh, GB
- Company size
- 11–50 employees
About Fios Genomics
We are a Bioinformatics Provider with clients in the UK, Europe and America. With over 17 years of experience in supporting scientists, researchers and bioinformaticians in data analysis, we have an extensive experience in handling all types of datasets for drug discovery & development, diagnostics, agricultural research, veterinary medicine and applied research across all species. Our specialised team of bioinformaticians, statisticians and biologists are able to analyse and interpret any genomic, transcriptomic, proteomic & metabolomic data, independent of the platform used. We are very well appreciated among our clients for our proprietary computer solutions that allow parallelisation of large datasets analysis that saves processing time and avoids the complications that arise when analysing data in batches. Results of the analysis are always presented in a secure web report that is complete with all references and results. Types of services offered by Fios Genomics: ● Technology/Platform Selection ● Study Design & Biostatistics ● Data QC and Pre-processing ● Biomarker Identification & Validation ● Genomic Signature Development ● Data Visualisation ● Preclinical Safety & Toxicology Investigations ● Clinical Trial Analysis ● Drug Repurposing For more info, get in touch: https://www.fiosgenomics.com/contact-us/ Office Address: Fios Genomics Ltd, Nine Edinburgh BioQuarter, 9 Little France Road, Edinburgh, EH16 4UX Bluesky: @fiosgenomics.bsky.social YouTube: https://www.youtube.com/@fiosgenomics
See moreLatest activity
Latest activity from Fios Genomics
4 signals
Research & Knowledge
Fios Genomics is integrating literature-derived insights with transcriptomics, single-cell sequencing, proteomics, and pathway analysis to validate literature-prioritized targets, identify robust biomarkers, build evidence-backed repurposing strategies, and prioritize candidates with greater confidence.
Presence & Recognition
Fios Genomics CEO Sarah Lynagh will chair the Precision Medicine Specialty Panel at BioInsight 2026 in Glasgow.
Research & Knowledge
Fios Genomics published a study using PANDORA-seq in hypopharyngeal carcinoma to identify 4,798 differentially expressed small non-coding RNAs.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
SOPHiA GENETICS
SOPHiA GENETICS published exploratory research in Clinical Cancer Research examining how integrated analysis of clinical, genomic, and biomarker data supports understanding of patient heterogeneity in advanced solid tumors treated with combination immunotherapy.
Research & Knowledge
Cure51
Cure51 published a Rosalind Study combining multiple layers of patient data, including genomics, transcriptomics, pathology, clinical history, and multi-omics insights, to integrate complex datasets and identify patterns for AI-driven treatment prediction.
Research & Knowledge
Biofidelity
Biofidelity published a collaborative study between Biofidelity and AstraZeneca demonstrating how mutated DNA enrichment combined with shallow targeted sequencing can enable highly sensitive detection of circulating tumour DNA in non-small cell lung cancer.
Research & Knowledge
1Cell.Ai Inc.
1Cell.Ai Inc. published a study in Cancer Research, an AACR Journals, highlighting the potential of comprehensive ctDNA profiling in treatment-naïve patients with early-stage breast cancer.
Research & Knowledge
Altum Sequencing